<DOC>
	<DOCNO>NCT01934738</DOCNO>
	<brief_summary>The purpose study investigate safety , toleration time course plasma concentration multiple oral dos PF-06273340 14 day healthy subject two age group , age 18-55 year ( Group 1 ) age 56-75 year ( Group 2 )</brief_summary>
	<brief_title>A Study Evaluate Safety , Toleration Time Course Plasma Concentration Multiple Oral Doses PF-06273340 Healthy Subjects Two AgeGroups , Aged 18-55 Years ( Group 1 ) Aged 56-75 Years ( Group 2 )</brief_title>
	<detailed_description />
	<criteria>For Group 1 specific : Healthy male and/or female subject nonchildbearing potential age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . For Group 2 specific : Healthy male and/or female subject nonchildbearing potential age 56 75 year , inclusive . Subjects must reasonably good health determine investigator base detailed medical history , full physical examination ( include blood pressure pulse rate measurement ) , 12lead ECG clinical laboratory test . Subjects mild , chronic , stable disease ( eg , osteoarthritis ) may enrol deem medically prudent investigator . In order ensure age range relevant osteoarthritis ( OA ) population , least 50 % subject enrol cohort must 60 year age Screening . For Group 2 specific : Subjects take daily prescription nonprescription medication management acceptable chronic medical condition must stable dose , define non change dose 3 month prior first dose study medication plan change conduct study . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption ( eg , gastrectomy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Multiple dose</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>PK</keyword>
</DOC>